TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01545986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants attended standardized exercise (ex) sessions twice a week for six weeks for 12 sessions. Group speed differed for concentric contractions, sit to stand ex, walking, curbs, and stairs. The low velocity ex group performed a concentric contraction in two seconds, and high velocity group in one second or less. End range concentric hold, eccentric contraction, repetition (rep) rest and set rest were the same. Open chain ex was performed at 50% of one Repetition Maximum (RM) x 10 reps x one set and then 80% of 1RM x 10 reps x two sets. Curb height and 1RM was assessed at the first, fifth and ninth sessions. Manual stretching, balance ex, sit to stand support, level of aerobic ex, gait training, and functional training were assessed and progressed at any session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants attended standardized exercise (ex) sessions twice a week for six weeks for 12 sessions. Group speed differed for concentric contractions, sit to stand ex, walking, curbs, and stairs. The low velocity ex group performed a concentric contraction in two seconds, and high velocity group in one second or less. End range concentric hold, eccentric contraction, repetition (rep) rest and set rest were the same. Open chain ex was performed at 50% of one Repetition Maximum (RM) x 10 reps x one set and then 80% of 1RM x 10 reps x two sets. Curb height and 1RM was assessed at the first, fifth and ninth sessions. Manual stretching, balance ex, sit to stand support, level of aerobic ex, gait training, and functional training were assessed and progressed at any session.
Study: NCT00040937

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: PBSC collection: 10 mcg/kg SQ days 1-10

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: PBSC collection: 500 mcg/m2 SQ day 1 through last apheresis~1st and 2nd trans: 500 mcg SC or IV days 6-WBC recovery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: PBSC collection: 1 mg/m2 IV over 45-60 mins day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg/d PO days 1-4, 9-12, 17-20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 1. st trans: 140 mg/m2 IV over 20 mins day -1~2. nd trans: 200mg/m2 IV over 20 mins day -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: maint: 50 mg/d PO every other day until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: ind: 50 mg increased by 50 mg every week to max 400 mg PO qhs for 35 days maint: 50 mg/d increased by 50 mg every week to 200 mg PO daily until progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: 2-4 x 10\^6/kg IV day 0
Study: NCT03198949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afinitor (everolimus)
Description: Everolimus doses will be 4.5mg/m2 po daily given at first time and then during the 4-week titration period everolimus dose may get adjusted to reach trough concentration of 5 - 15 ng/mL.~(In order to keep the blind, placebo doses will be also adjusted during core phase based on a random scheme of dose changes.)
Study: NCT02576665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toca 511
Description: Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-fluorocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Furosemide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apple compote Furosemide
Study: NCT03198949

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Afinitor (everolimus)
Description: Everolimus doses will be 4.5mg/m2 po daily given at first time and then during the 4-week titration period everolimus dose may get adjusted to reach trough concentration of 5 - 15 ng/mL.~(In order to keep the blind, placebo doses will be also adjusted during core phase based on a random scheme of dose changes.)
Study: NCT02853591

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumoinsufflator mode and setting
Description: Patients undergoing total laparoscopic hysterectomy will be randomized to pneumoperitoneum creation by one of two modes (standard or pressure-barrier) at one of two set pressures (15mmHg or 9mmHg) for a four-armed factorial designed study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumoinsufflator mode and setting
Description: Patients undergoing total laparoscopic hysterectomy will be randomized to pneumoperitoneum creation by one of two modes (standard or pressure-barrier) at one of two set pressures (15mmHg or 9mmHg) for a four-armed factorial designed study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumoinsufflator mode and setting
Description: Patients undergoing total laparoscopic hysterectomy will be randomized to pneumoperitoneum creation by one of two modes (standard or pressure-barrier) at one of two set pressures (15mmHg or 9mmHg) for a four-armed factorial designed study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumoinsufflator mode and setting
Description: Patients undergoing total laparoscopic hysterectomy will be randomized to pneumoperitoneum creation by one of two modes (standard or pressure-barrier) at one of two set pressures (15mmHg or 9mmHg) for a four-armed factorial designed study.
Study: NCT04683536

Intervention type: PROCEDURE
Intervention: Obturator nerve blockade
Description: We performed spinal anesthesia combined with ultrasound guided obturator nerve blockade according to the localization of bladder cancer in patients with lateral wall localized non-muscle invasive bladder cancer

Intervention type: PROCEDURE
Intervention: Obturator nerve blockade
Description: We performed spinal anesthesia combined with ultrasound guided obturator nerve blockade according to the localization of bladder cancer in patients with lateral wall localized non-muscle invasive bladder cancer
Study: NCT01737515

Intervention type: OTHER
Intervention: Abdominal waist and hip circumference
Description: Abdominal waist and hip circumferences are measured clinically with a ruler as part of the standard pre-operative physical examination
Study: NCT00237757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information feedback
Description: The experimental arm consisted of a six month staff training period. The core of the intervention consisted of a concentrated 2.5 day workshop in Atlanta for 29 rehabilitation team leaders from 15 VA hospitals. Several weeks after the workshop, participants received a custom action plan developed on issues discussed in the workshop. The experimental arm also received a summary of results of the initial survey along with comparative data from all other sites. During the subsequent 5 months after the workshop, research staff maintained regular contact with research participants through telephone and videoconferencing. The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information feedback
Description: The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes. In addition, participants in the comparison arm were invited to contact the research staff for help in interpreting data or to set-up a process improvement initiative.
Study: NCT01770548

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: analysis of the glutamate synapse in autism
Description: Neurophysiological, molecular and developmental analysis of the glutamate synapse in autism

Intervention type: GENETIC
Group type: OTHER
Intervention: analysis of the glutamate synapse in autism
Description: Neurophysiological, molecular and developmental analysis of the glutamate synapse in autism

Intervention type: GENETIC
Group type: OTHER
Intervention: analysis of the glutamate synapse in autism
Description: Neurophysiological, molecular and developmental analysis of the glutamate synapse in autism

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA collection
Description: DNA collection

Intervention type: GENETIC
Group type: OTHER
Intervention: DNA collection
Description: DNA collection

Intervention type: GENETIC
Group type: OTHER
Intervention: DNA collection
Description: DNA collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory evoked potentials
Description: auditory evoked potentials

Intervention type: OTHER
Group type: OTHER
Intervention: Auditory evoked potentials
Description: auditory evoked potentials

Intervention type: OTHER
Group type: OTHER
Intervention: Auditory evoked potentials
Description: auditory evoked potentials

Intervention type: OTHER
Group type: OTHER
Intervention: Auditory evoked potentials
Description: auditory evoked potentials
Study: NCT02570581

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apple compote Furosemide
Study: NCT04774874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical formulation
Description: Topical administration on the scalp once daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical formulation
Description: Topical administration on the scalp once daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical formulation
Description: Topical administration on the scalp once daily for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical formulation
Description: Topical administration on the scalp once daily for 16 weeks
Study: NCT01942187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Medication augmentation with Abilify (aripiprazole), in participants who have not responded to Selective Serotonin Reuptake Inhibitor (SSRI) treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Medication augmentation with Wellbutrin (bupropion), in participants who have not responded to SSRI treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Therapy
Description: Weekly specialized psychotherapy
Study: NCT01045889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rituximab and CHOP regimen + PBSCT
Study: NCT01399138

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry Powder
Description: The groups will be randomized to receive 45g of blueberry powder or control (i.e., placebo) per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The second smoothie will be consumed at least 6 hours from the first smoothie. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Blueberry Powder
Description: The groups will be randomized to receive 45g of blueberry powder or control (i.e., placebo) per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The second smoothie will be consumed at least 6 hours from the first smoothie. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients
Study: NCT04075565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Terrestrial altitude
Description: Terrestrial altitude: The volunteers are in an SAC hut at an altitude of 3000 m. By means of this exposure the psychophysiological effect under hypobaric and hypoxic conditions is determined. The subjects spend the night in this SAC hut and the measurements are repeated the next day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cloud 9
Description: Cloud 9 is a solid, certified product that complies with European Directives on Electromagnetic Compatibility, Machine Directive, Air Pressure Equipment and Low Voltage Equipment (89/336 / EEC, 91/368 / CEE, 93/68 / CEE, 97/23 / EC, EN61010-1 All directives are in writing in the Supplements to this Ethics Application.~Simulated height: The subjects are in the laboratory of our institution and are connected to the Cloud 9 by means of a mask. Subjects are exposed to a simulated altitude of 3530m under normobaric conditions. By means of this intervention the psychophysiological effect under normobaric and hypoxic conditions is determined.
Study: NCT03641651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation technology
Description: * Series of tailored rehabilitative training with the use of new technology which provide feedback and allow for a targeted and intensive and dense training.~* With supervision based on patients preconditions and therapy device (e.g. patient/ therapist ratio= 3/1).~* A training series lasts four weeks and comprises 3-5 training-days per week. Maximum training break of 7 days.~Five sessions of training with duration of 45 min per session, and up to four hours each day are foreseen.~* The training can take place in an outpatient or inpatient setting.~* Training will be organized in individual one-to-one or group session
Study: NCT01974583

Intervention type: PROCEDURE
Intervention: regrafted with thin split-thickness skin graft
Description: Group A (the treatment group) were regrafted with thin split-thickness skin graft

Intervention type: PROCEDURE
Intervention: covered with the occlusive hydrocellular dressing
Description: group B covered with the occlusive hydrocellular dressing (Allevyn Adhesive, Smith \& Nephew)

Intervention type: PROCEDURE
Intervention: covered with paraffin gauze
Description: Group C covered with paraffin gauze
Study: NCT04602832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19
Description: ENHANCE is a 12-session program designed to help improve subjective well-being, especially through the challenges of a pandemic. The ENHANCE program introduces and teaches people about the evidence-based principles and skills that have been shown across decades of research to improve overall health and well-being.
Study: NCT03019302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrow PICC with Chloragard Technology
Description: chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body
Study: NCT04099927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0410
Description: SHR0410 monotherapy,given intravenously
Study: NCT01430091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel (clinical formulation)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel (Orally Disintegrating Tablet [ODT])
Description: Administered orally
Study: NCT01430091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel (Orally Disintegrating Tablet [ODT])
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel (Orally Disintegrating Tablet [ODT])
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel (Orally Disintegrating Tablet [ODT])
Description: Administered orally
Study: NCT04840238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 30,000IU cholecalciferol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT03072628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-cig with nicotine
Description: use an e-cig with nicotine for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-cig without nicotine
Description: use an e-cig without nicotine for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nicotine inhaler
Description: use a nicotine inhaler for 30 minutes

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham control
Description: use an empty e-cigarette for 30 minutes
Study: NCT01080404

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: The patients are given standardized CPAP treatment according to current clinical guidelines.
Study: NCT03608436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low pressure pneumoperitoneum
Description: Lowering intra-abdominal pressure during laparoscopic surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Bromide
Description: Deep (PTC 1-2) versus moderate (Tof count 1-2) neuromuscular block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium Bromide
Description: Deep (PTC 1-2) versus moderate (Tof count 1-2) neuromuscular block
Study: NCT02624830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: See Arm description.
Study: NCT02542696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-130277
Description: Used to treat up to 5 OFF episodes per day
Study: NCT02989324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MisoprostoL
Description: Vaginal MisoprostoL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter
Description: Misoprostol Plus Foley Catheter
Study: NCT00501293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Transdermal System
Description: One of 4 doses of the MTS transdermal patch over the same duration of wear for approximately 6 months
Study: NCT01075724

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Warming with Forced Air
Description: Forced Air warming via BairHugger

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resistive Warming
Description: Resistive Warming via HotDog device
Study: NCT02895906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFC-1
Description: Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as size 2, hard gelatin capsules for oral administration.
Study: NCT01856062

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo with similar appearance to dexamethasone will be given with a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral dexamethasone will be added to a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
Study: NCT04413994

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Humavant
Description: Premature infants are randomized to either:~1. An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and the human milk fortifier until 36 weeks of gestation; OR~2. Human milk (as long as available) and the human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.~After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included.
Study: NCT02576665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toca FC
Description: Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side
Study: NCT02357862

Intervention type: PROCEDURE
Intervention: Mitral Valve Annuloplasty
Description: Mitral valve annuloplasty by a rigid mitral ring, a semi-rigid ring, or a fully flexible band, at the surgeon's discretion
Study: NCT00655343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-Fresenius S
Description: 20 mg rabbit immunoglobulin (IgG) in 1 ml of sterile solution~20 mg/kg body weight per day diluted in 500 ml physiological saline, slow intravenous infusion at days -3, -2, -1 prior to transplantation
Study: NCT02006225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Study: NCT02312219

Intervention type: DRUG
Intervention: Folic Acid
Description: 1 mg folic acid once daily

Intervention type: DRUG
Intervention: Folic Acid
Description: 1 mg folic acid once daily

Intervention type: DRUG
Intervention: Placebo
Description: placebo once weekly

Intervention type: DRUG
Intervention: Low Dose Methotrexate
Description: An anti-inflammatory drug
Study: NCT01228994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen 30 mg/day
Description: Baclofen 30 mg/day for 8 weeks with 2 week induction and 2 week decrease

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo pill
Description: placebo pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen 60 mg/day
Description: baclofen 60 mg/day for 8 weeks with 2 week induction and 2 week decrease
Study: NCT03100812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: More intensive CHW Intervention
Description: Group A participants will attend 4 monthly 90 minute group health education sessions that provide the tools and strategies to promote heart health to Filipino American individuals, families, and communities on high blood pressure and CVD. The CHWs will lead these sessions utilizing NHLBI's Healthy Heart Healthy Family, A CHW's Manual for the Filipino Community. Each of the group health education sessions will discuss different content related to CVD, hypertension, and other CVD risk factors. The first session focuses on assessing heart disease risk and recognition of heart attack signs. The second session focuses on physical activity and weight management and blood pressure control. The third session addresses control of cholesterol, and diabetes. The final 4th session teaches participants about nutrition and living smoke free.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Less Intensive CHW Intervention
Description: Individuals randomized to the less intensive CHW intervention will have the baseline, 4 month, and 8 month interviews and blood pressure measurements will be collected in those succeeding time points. Participants will also receive a 30 minute one on one session from the CHW and a referral to a physician if needed.